Denali Therapeutics (DNLI)
20.14
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K Denali Therapeutics Inc. For: Jun 03
June 4, 2026 6:02 AM - SEC Filing
Denali Therapeutics Inc. (DNLI) PT Lowered to $28 at Evercore ISI
May 27, 2026 1:47 PM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Lowered to $35 at Morgan Stanley
May 26, 2026 7:44 AM - StreetInsider
Form 8-K Denali Therapeutics Inc. For: May 21
May 22, 2026 6:01 AM - SEC Filing
Biogen and Denali discontinue Parkinson's drug after trial fails
May 21, 2026 6:00 PM - StreetInsider
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026 6:00 PM - StreetInsider
Form SCHEDULE 13G Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.
May 15, 2026 10:07 AM - SEC Filing
Denali Therapeutics Inc. (DNLI) PT Lowered to $40 at Morgan Stanley
May 14, 2026 8:52 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 3c
May 7, 2026 5:57 PM - StreetInsider
Form 10-Q Denali Therapeutics Inc. For: Mar 31
May 7, 2026 4:14 PM - SEC Filing
Form 8-K Denali Therapeutics Inc. For: May 07
May 7, 2026 4:04 PM - SEC Filing
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026 4:01 PM - StreetInsider
Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: FMR LLC
May 6, 2026 11:14 AM - SEC Filing
Form 3/A Denali Therapeutics Inc. For: Apr 10 Filed by: Chin Peter Scott
April 21, 2026 7:21 PM - SEC Filing
Form DEFA14A Denali Therapeutics Inc.
April 21, 2026 4:34 PM - SEC Filing
Form ARS Denali Therapeutics Inc. For: Dec 31
April 21, 2026 4:33 PM - SEC Filing
Form DEF 14A Denali Therapeutics Inc. For: Dec 31
April 21, 2026 4:33 PM - SEC Filing
Form 3 Denali Therapeutics Inc. For: Apr 10 Filed by: Chin Peter Scott
April 20, 2026 7:22 PM - SEC Filing
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026 8:30 AM - Globe NewsWire
Denali Therapeutics Inc. (DNLI) PT Raised to $34 at Baird
April 7, 2026 6:15 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $39 at BTIG
April 6, 2026 1:00 PM - StreetInsider
Denali regains full rights to brain therapy after Takeda ends partnership
April 6, 2026 5:55 AM - StreetInsider
Form 8-K Denali Therapeutics Inc. For: Apr 03
April 3, 2026 2:44 PM - SEC Filing
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 3, 2026 1:30 PM - StreetInsider
Form 8-K Denali Therapeutics Inc. For: Mar 27
March 31, 2026 8:30 AM - SEC Filing
Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: VANGUARD GROUP INC
March 26, 2026 6:07 PM - SEC Filing
Denali Therapeutics Inc. (DNLI) PT Raised to $31 at BofA Securities
March 26, 2026 9:45 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $42 at H.C. Wainwright
March 26, 2026 8:35 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $42 at Morgan Stanley
March 26, 2026 8:19 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $32 at Baird
March 26, 2026 6:16 AM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $41 at Stifel
March 25, 2026 4:13 PM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $40 at Goldman Sachs
March 25, 2026 4:02 PM - StreetInsider
Form 8-K Denali Therapeutics Inc. For: Mar 25
March 25, 2026 3:13 PM - SEC Filing
Denali Therapeutics Inc. (DNLI) PT Raised to $38 at BTIG
March 25, 2026 3:11 PM - StreetInsider
Denali shares jump on FDA approval of Hunter syndrome drug
March 25, 2026 1:05 PM - StreetInsider
Denali Therapeutics Inc. (DNLI) PT Raised to $40 at Oppenheimer
March 25, 2026 12:38 PM - StreetInsider
Denali Therapeutics gains FDA approval for Hunter syndrome drug AVLAYAH
March 25, 2026 11:50 AM - StreetInsider
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026 11:50 AM - Globe NewsWire
Full Article List
